Global Celiac Disease Drugs Market 2022-2026 - A Robust Pipeline and Rise in Pharmaceutical Expenditure will Lead to Sizable Demand - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Celiac Disease Drugs Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

The celiac disease drugs market is poised to grow by $601.57 mn during 2022-2026, accelerating at a CAGR of 16.95%

This study identifies the inorganic growth strategies as one of the prime reasons driving the celiac diseases drugs market growth during the next few years. Also, a robust pipeline and rise in pharmaceutical expenditure will lead to sizable demand in the market.

The market is driven by higher consumption of gluten-containing food, increasing prevalence of celiac disease, and government initiatives.

The report on the celiac disease drugs market provides a holistic analysis, of market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The celiac disease drugs market analysis includes type segment and geographic landscape.

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading celiac diseases drugs market vendors.

Also, the celiac disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

Key Topics Covered:

1 Executive Summary

1.1 Market overview

2 Market Landscape

2.1 Market ecosystem

3 Market Sizing

3.1 Market definition

3.2 Market segment analysis

3.3 Market size 2021

3.4 Market outlook: Forecast for 2021-2026

4 Five Forces Analysis

4.1 Five forces summary

4.2 Bargaining power of buyers

4.3 Bargaining power of suppliers

4.4 Threat of new entrants

4.5 Threat of substitutes

4.6 Threat of rivalry

4.7 Market condition

5 Market Segmentation by Therapy

5.1 Market segments

5.2 Comparison by Therapy

5.3 First line treatment - Market size and forecast 2021-2026

5.4 Second line treatment - Market size and forecast 2021-2026

5.5 Market opportunity by Therapy

6 Customer Landscape

6.1 Customer landscape overview

7 Geographic Landscape

7.1 Geographic segmentation

7.2 Geographic comparison

7.3 North America - Market size and forecast 2021-2026

7.4 Europe - Market size and forecast 2021-2026

7.5 Asia - Market size and forecast 2021-2026

7.6 Rest of World (ROW) - Market size and forecast 2021-2026

7.7 US - Market size and forecast 2021-2026

7.8 Canada - Market size and forecast 2021-2026

7.9 Germany - Market size and forecast 2021-2026

7.10 UK - Market size and forecast 2021-2026

7.11 France - Market size and forecast 2021-2026

7.12 Market opportunity By Geographical Landscape

8 Drivers, Challenges, and Trends

8.1 Market drivers

8.2 Market challenges

8.3 Impact of drivers and challenges

8.4 Market trends

9 Vendor Landscape

9.1 Overview

9.2 Vendor landscape

9.3 Landscape disruption

9.4 Industry risks

10 Vendor Analysis

10.1 Vendors covered

10.2 Market positioning of vendors

• 9 Meters Biopharma Inc.
• Adaptive Biotechnologies Corp.
• Almirall SA
• Amgen Inc.
• AMYRA Biotech AG
• Avaxia Biologics Inc.
• BioLineRx Ltd.
• Bristol Myers Squibb Co.
• Calypso Biotech
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd
• Immunogenics LLC
• Johnson and Johnson
• Precigen Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Vactech Oy
• Zedira GmbH
• Artielle Immunotherapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/r/8s5ne2

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900